Saturday, 18 November 2017

Early Career Professor Award to Dr Gary Patti by Agilent Technologies

11 July 2017 | News

Washington University in St. Louis Professor recognised for Ground-breaking work in Metabolomics

Source: Pixabay

Source: Pixabay

Dr. Patti, Associate Professor, Department of Chemistry Arts and Science, Washington University in St. Louis, was selected for his contributions to the detection of metabolomics changes in whole organisms and their utility for drug discovery, early detection, characterization and surveillance of cancer as well as other diseases and conditions.

Using state-of-the-art mass spectrometers coupled with cutting-edge metabolomic technologies, Dr. Patti’s lab takes a systems-level approach to the study of comprehensive metabolism and identification of specific pathways that are altered in connection with particular phenotypes.

Jack Wenstrand, Director, University Relations and External Research at Agilent said, “Agilent is pleased to recognize and support the work of Dr. Patti, who is developing and implementing experimental approaches that advance metabolomics analysis from the lab bench to translational applications in human disease”

Dr. William Buhro, Chairman, Department of Chemistry; George E. Pake Professor in Arts & Science Washington University in St. Louis said, "Metabolism is one of the most exciting areas in biochemical research. We are honored to have one of the world's best in metabolomics here in our department”

Established in 2008, annual Agilent Early Career Professor Award seeks to recognise the achievements of academic researchers in the initial stages of their careers and to support and develop strong collaborative relationships with them at the beginning of their professional lives.

This award underscores Agilent's commitment to furthering research through the company's products and services, financial support, and collaborative engagement by Agilent scientists and engineers.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Are Indian drug firms still cautious of executing big mergers & acquistions?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls